Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Metoclopramide
Drug ID BADD_D01442
Description Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system.[A184934] Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition to gastroesophageal reflux disease (GERD). It can also be used to prevent nausea or vomiting associated with chemotherapy or certain surgical or diagnostic procedures.[L8417] One unique property of this drug is that it does not increase gastric acid secretion. It is available in the oral tablet form or in solution, and can also be administered through the intravenous route.[T683] Metoclopramide was initially approved by the FDA in 1980.[A184922]
Indications and Usage Metoclopramide in the oral tablet form is used for symptomatic treatment of both acute and recurrent diabetic gastroparesis, in addition to the treatment of gastroesophageal reflux disease (GERD) in patients who have failed to respond to traditional therapy.[L8414] A nasal spray formulation is also indicated to treat adults with acute, recurrent diabetic gastroparesis.[L14381] In the intravenous injection form, it is indicated for the above conditions as well as for the prevention of vomiting that may follow emetogenic chemotherapy or nausea and vomiting after surgery. Intravenous metoclopramide facilitates intubation of the small bowel and stimulates gastric emptying and barium flow in patients who require radiological examination of the stomach or small intestine. In some cases, the delay of gastrointestinal emptying interferes with the radiographic visualization of the gastrointestinal tract, and metoclopramide is used to facilitate emptying in these cases, allowing for adequate diagnostic visualization.[L8417] Some off-label uses of metoclopramide include the management of radiation-induced nausea and vomiting, gastric bezoars, intractable hiccups, and migraine pain.[A184961,A184964,A184967,A40105]
Marketing Status approved; investigational
ATC Code A03FA01
DrugBank ID DB01233
KEGG ID D00726
MeSH ID D008787
PubChem ID 4168
TTD Drug ID D08VYV
NDC Product Code 49884-689; 51662-1367; 62559-296; 62559-295; 70518-0669; 71335-0362; 71335-0790; 0409-5255; 70518-1193; 71872-7076; 0615-8285; 50090-0132; 63629-2144; 49999-057; 60687-620; 0093-2204; 51079-886; 51079-888; 68788-7226; 51662-1288; 63187-235; 63629-8745; 0409-3414; 68788-7930; 0703-4502; 0093-2203; 51655-240; 55154-4383; 60687-631; 62559-190; 63629-1961; 63629-7967; 42291-596; 63187-404; 0615-7698; 43353-274
UNII L4YEB44I46
Synonyms Metoclopramide | 4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide | Metaclopramide | Maxolon | Rimetin | Metoclopramide Hydrochloride | Hydrochloride, Metoclopramide | Metoclopramide Monohydrochloride | Monohydrochloride, Metoclopramide | Metoclopramide Monohydrochloride, Monohydrate | Primperan | Reglan | Cerucal | Metoclopramide Dihydrochloride | Dihydrochloride, Metoclopramide
Chemical Information
Molecular Formula C14H22ClN3O2
CAS Registry Number 364-62-5
SMILES CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Toxic skin eruption10.01.01.008; 12.03.01.073; 23.03.05.0030.000196%-
Metabolic disorder14.11.01.0010.011939%-
Dysgraphia17.02.03.0060.000627%-
Restless legs syndrome15.05.03.012; 17.02.07.0080.007587%-
Cerebral vasoconstriction17.08.02.012; 24.04.06.0250.000294%-
Aortic rupture12.01.11.007; 24.03.04.0090.000490%-
Eye movement disorder06.05.02.008; 17.02.05.0250.000784%-
Mental disorder19.07.01.0020.010488%-
Porphyrin metabolism disorder03.08.01.006; 09.01.10.004; 14.14.01.006---
Decreased appetite08.01.09.028; 14.03.01.005--
Erectile dysfunction19.08.04.001; 21.03.01.007--
Parkinson's disease17.01.05.0100.009665%-
Blood disorder01.05.01.004---
Grimacing17.02.05.029---
Hyperlipidaemia14.08.03.0010.000196%
Renal impairment20.01.03.010---
Unevaluable event08.01.03.0510.019938%-
Muscle contracture15.03.05.0240.000294%-
Facial spasm17.04.03.0100.000294%-
Low birth weight baby18.04.02.0030.000392%-
Oral disorder07.05.01.0050.000588%-
Spasmodic dysphonia17.01.03.007; 22.12.03.0260.000294%-
Upper airway obstruction22.12.03.032---
Oromandibular dystonia17.01.03.0060.000490%-
Kounis syndrome02.02.02.020; 10.01.03.037; 24.04.04.0200.000686%-
Foetal growth restriction18.03.01.0020.000196%
Functional gastrointestinal disorder07.11.01.016---
Resting tremor17.01.06.0080.001294%-
Drug-induced liver injury09.01.07.023; 12.03.01.0440.000784%-
Multiple organ dysfunction syndrome08.01.03.0570.000686%
The 8th Page    First    Pre   8 9    Next   Last    Total 9 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene